mRNA cancer vaccine ยท vaccine
BNT116
1 active trials across 3 of our biomarkers, targeting tumour antigens. Not approved for any biomarker on marked.bio yet.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| ALK fusion | 1 | 1 | Phase 1 |
| EGFR exon 19 deletion / L858R | 1 | 1 | Phase 1 |
| RET fusion or mutation | 1 | 1 | Phase 1 |
Sponsors
Industry sponsors leading active biomarker-selected trials of BNT116.
- BioNTech 1
Trials
1 of 1 trials shown
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
BNT116cemiplimabdocetaxelcarboplatinpaclitaxelgotistobartanti-B7-H3 antibody conjugated to topoisomerase I inhibitoranti-HER3 antibody conjugated to topoisomerase I inhibitorBispecific antibody for PD-L1 and VEGF-Aosimertinib FDA EUALK-inhibitor or RET-inhibitor
Participants' NSCLC must have classical EGFR mutations, i.e., ex19Del or L858R.
EGFR exon 19 deletion / L858RALK fusionRET fusion or mutationNon-Small Cell Lung Cancer
No trials match these filters.